Dupixent Lymphoma Lawsuit Update (2026): Texas & Nationwide Claims for CTCL, Mycosis Fungoides, and Sézary Syndrome

By Dr. Shezad Malik, M.D., J.D. — Board‑Certified Physician & Product Liability Trial Attorney

Dupixent® (dupilumab) is one of the most commonly prescribed biologic medications for eczema, asthma, and chronic sinus disease.

A medical‑legal expert analyzes dermatopathology slides and CTCL biopsy findings linked to Dupixent‑related lymphoma claims.

But thousands of patients across the United States have reported a dangerous and unexpected complication: the development or acceleration of rare skin lymphomas, including Cutaneous T‑Cell Lymphoma (CTCL), Mycosis Fungoides, Sézary Syndrome, and other T‑cell cancers.

As a board‑certified physician and product liability trial attorney based in Dallas with a nationwide practice, I help patients understand whether their cancer diagnosis may be linked to Dupixent — and help them file a Dupixent Lymphoma Lawsuit and qualify for financial compensation through the growing federal litigation.

1. Why Dupixent Is Linked to Skin Lymphoma

Dupixent blocks two immune system signals — IL‑4 and IL‑13 — that drive inflammation. While this helps control eczema, it also changes how the immune system monitors abnormal skin cells. In some patients, this shift may allow pre‑existing cancer cells to grow unchecked.

Many early lymphoma symptoms look exactly like eczema: red patches, scaly plaques, itching, or skin thickening. This overlap can delay diagnosis for months or years.

2. Key Medical Studies Linking Dupixent to Lymphoma

Multiple peer‑reviewed studies have documented increased lymphoma risks among Dupixent users. Here are the most important findings:

3. FDA Safety Signals & FAERS Reports

The FDA added Dupixent to its official list of drugs with “Potential Signals of Serious Risks” after receiving more than 300 detailed lymphoma reports from dermatologists and oncologists nationwide.

Because FAERS captures only 1–10% of real‑world injuries, the true number of affected patients is likely far higher.

4. Legal Allegations Against Sanofi & Regeneron

Current lawsuits allege the manufacturers:

• Failed to warn doctors to perform skin biopsies before prescribing Dupixent.
• Ignored post‑marketing safety signals linking the drug to lymphoma.
• Marketed Dupixent as safe for long‑term use despite emerging cancer risks.

5. MDL No. 3180 — Federal Dupixent Litigation

All federal Dupixent lymphoma lawsuits are consolidated under MDL No. 3180 in the U.S. District Court for the District of New Jersey, overseen by Judge Zahid N. Quraishi.

As of mid‑2026, 26 cases are pending, with more filed every month.

6. Real Patient Examples From Across the U.S.

Below are real lawsuit examples showing how Dupixent‑related cancer claims are emerging nationwide:

• Tennessee: Patient developed Mycosis Fungoides 8 months after starting Dupixent.
• Louisiana: Patient misdiagnosed with eczema for years until CTCL was discovered.
• Texas: Multiple patients reporting rapid disease progression during Dupixent therapy.
• Ohio: A 59‑year‑old man developed Sézary Syndrome after 14 months on Dupixent; oncologists noted “immune pathway disruption.”
• Florida: A woman treated for chronic eczema developed aggressive CTCL requiring radiation and systemic therapy.
• California: A 42‑year‑old patient developed peripheral T‑cell lymphoma after Dupixent was prescribed without a baseline biopsy.
• New York: A long‑term Dupixent user developed widespread plaques later confirmed as Mycosis Fungoides.
• Georgia: A patient developed rapid‑onset CTCL after Dupixent suppressed visible inflammation, delaying diagnosis.
• Illinois: A man developed lymphadenopathy and CTCL after two years of Dupixent injections.

7. Statute of Limitations by State (Quick Guide)

Every state enforces strict deadlines for filing product liability and injury claims. Missing your deadline permanently bars recovery.

If your state is not listed, contact our office — we handle nationwide claims and can confirm your deadline.

💬 Frequently Asked Questions — Dupixent Lymphoma Lawsuits

8. Why Choose a Physician‑Attorney?

As both a medical doctor and trial attorney, I personally review your biopsies, oncology records, and medication timeline to build a strong causation argument — without outsourcing your medical analysis to third‑party consultants.

This dual‑discipline approach is especially important in Dupixent cases, where the defense often argues that lymphoma was “pre‑existing” or “unrelated.” A physician‑attorney can dismantle these claims using:

• T‑cell clonality testing
• Biopsy progression timelines
• Dermatopathology interpretation
• Immune pathway analysis

9. Compensation Available

• Medical bills (oncology, radiation, chemotherapy)
• Lost wages and future earning capacity
• Pain, suffering, and permanent skin damage
• Wrongful death damages for families

Contact a Dupixent Lymphoma Lawyer Today

If you or a loved one developed CTCL, Mycosis Fungoides, or Sézary Syndrome after using Dupixent, contact our office immediately.

Call 214‑390‑3189 or visit shezadmalik.com for a free, confidential case review.

Read More Here

Dupixent Lymphoma Lawsuit: Claims, Risks & Financial Compensation Options

California Viagra Skin Cancer Lawsuit

Roundup Non-Hodgkin’s Cancer Lawsuit Update